CAM
CRSP icon

Costello Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Costello Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.5K Hold
600
– – 0.01% 325
2025
Q4 		$31.5K Sell
600
-200
-25% -$12K 0.01% 305
2025
Q3 		$51.8K Hold
800
– – 0.02% 233
2025
Q2 		$38.9K Hold
800
– – 0.01% 272
2025
Q1 		$27.2K Buy
+800
New +$33.9K 0.01% 308

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Costello Asset Management's CRSP Position: Q1 2026 in Review

Costello Asset Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 600 shares worth $28.5K. The position accounts for 0.01% of the portfolio, ranked #325.

Costello Asset Management first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. The position peaked at $51.8K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Costello Asset Management held 600 shares of CRISPR Therapeutics worth $28.5K as of Q1 2026.
  • Costello Asset Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up 0.01% of Costello Asset Management's portfolio in Q1 2026, its #325 holding.
  • Costello Asset Management first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Costello Asset Management's CRISPR Therapeutics position peaked at $51.8K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Costello Asset Management's 13F filing for Q1 2026, filed 30 Apr 2026.